Candriam S.C.A. Has $54.24 Million Holdings in Zoetis Inc. $ZTS

Candriam S.C.A. trimmed its stake in Zoetis Inc. (NYSE:ZTS) by 12.9% during the first quarter, HoldingsChannel.com reports. The fund owned 458,854 shares of the company’s stock after selling 67,878 shares during the quarter. Candriam S.C.A.’s holdings in Zoetis were worth $54,241,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZTS. Arbor Capital Management Inc. ADV grew its holdings in shares of Zoetis by 3.8% in the 1st quarter. Arbor Capital Management Inc. ADV now owns 6,782 shares of the company’s stock worth $813,000 after purchasing an additional 247 shares during the last quarter. Hsbc Holdings PLC boosted its position in Zoetis by 55.8% in the first quarter. Hsbc Holdings PLC now owns 2,063,170 shares of the company’s stock valued at $243,720,000 after buying an additional 739,060 shares in the last quarter. Waterfront Wealth Inc. boosted its position in Zoetis by 5.5% in the first quarter. Waterfront Wealth Inc. now owns 11,395 shares of the company’s stock valued at $1,347,000 after buying an additional 589 shares in the last quarter. Peterson Wealth Services grew its stake in Zoetis by 43,297.3% during the first quarter. Peterson Wealth Services now owns 16,057 shares of the company’s stock worth $1,898,000 after buying an additional 16,020 shares during the last quarter. Finally, Griffin Asset Management Inc. increased its holdings in shares of Zoetis by 2.7% during the first quarter. Griffin Asset Management Inc. now owns 32,996 shares of the company’s stock worth $3,900,000 after buying an additional 864 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Insider Activity at Zoetis

In other Zoetis news, Director Frank A. Damelio bought 6,650 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were bought at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the transaction, the director owned 21,458 shares in the company, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Paul Bisaro bought 2,000 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the purchase, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 11,650 shares of company stock worth $886,384 over the last 90 days. Insiders own 0.22% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on ZTS shares. UBS Group cut their target price on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Stifel Nicolaus dropped their price target on Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a report on Friday, June 26th. Weiss Ratings downgraded Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. Morgan Stanley reissued an “overweight” rating and issued a $115.00 price objective on shares of Zoetis in a research note on Friday, May 15th. Finally, Argus restated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Hold” and an average target price of $123.46.

Zoetis Price Performance

ZTS opened at $75.49 on Friday. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The stock has a market capitalization of $31.65 billion, a P/E ratio of 12.52, a price-to-earnings-growth ratio of 1.17 and a beta of 0.75. The company’s 50 day simple moving average is $79.96 and its 200-day simple moving average is $107.76. Zoetis Inc. has a one year low of $71.47 and a one year high of $160.48.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.8%. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: No clearly positive company-specific catalysts were reported in the latest batch of articles.
• Neutral Sentiment: Multiple law firms, including Rosen, Glancy Prongay, Bragar Eagel & Squire, The Gross Law Firm, Kessler Topaz, Schall, Howard G. Smith, and Bernstein Liebhard, are urging investors who bought ZTS shares during the class period to contact them before the July 27 lead plaintiff deadline.
• Negative Sentiment: A class action lawsuit has been filed against Zoetis and certain officers, with allegations of material misstatements and/or omissions tied to product adoption, which may increase legal costs and pressure the stock. Article Title

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.